Pharmaceutical

STAT+: Allogene to pursue new strategy for development ...

“The CAR-T space has become very crowded,” said David Chang, in announcing a str...

Baby monitor videos yield evidence for long-suspected l...

“It was the videos alone that implicated seizures. Otherwise, we would have not ...

STAT+: Feng Zhang’s year-old CRISPR delivery startup Ae...

Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang, has laid...

STAT+: Another major pharma company departs BIO

UCB left the biotech industry group BIO at the end of 2023, the second major mem...

STAT+: FDA is blasted by advocates for pursuing a deal ...

Advocacy groups are blasting the FDA's plan to work with a Denver Health surveil...

Why CG Oncology will be the first test of 2024’s IPO wa...

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: We’re reading about CVS dropping H...

CVS Health will no longer offer AbbVie's Humira to patients in its commercial pr...

STAT+: An injectable gel enters the male birth control ...

An injectable, reversible hydrogel made by Contraline could fill the male birth ...

STAT+: Feng Zhang, Grail founder join forces on new gen...

A new startup co-founded by Feng Zhang aims to develop treatments for a variety ...

STAT+: Novo Nordisk enlists two Flagship biotechs to de...

The Danish drugmaker Novo Nordisk is enlisting two Flagship biotechs to develop ...

STAT+: Burning questions for the 2024 JPM Healthcare Co...

Here’s our list of burning questions facing the health care industry as much of ...

Opinion: Insurance companies are forcing psychiatrists ...

Insurance companies are forcing psychiatrists to stop accepting their coverage.

STAT+: Health tech’s 2024 hiring outlook: Balance tips ...

It might feel like a downturn, but more likely, the health technology industry i...

After loved ones’ long-awaited organ transplants, careg...

Caregivers for people who receive organ transplants say there is often little su...

STAT+: Veteran biotech entrepreneur Harvey Berger to le...

Veteran biotech entrepreneur Harvey Berger is the new chief executive of venture...

Anavex’s slow journey to failure

Want to stay on top of the science and politics driving biotech today? Sign up t...